• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report finds pharma companies limited January list price hikes

February 27, 2017 By Sarah Faulkner

Report finds pharma companies limited January list price hikesDrug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago.

However, the median drug-price increase held steady compared to last year at 8.9% – far exceeding the U.S. inflation rate of 2%.

Price increases held below 10% can still drive up total drug spending by hundreds of millions of dollars, according to the Wall Street Journal. AbbVie (NYSE:ABBV) raised the list price of its arthritis treatment, Humira, by 8.4% in January, and could bring in as much as $850 million in additional U.S. health-care spending.

AbbVie and other pharmaceutical companies, including Mylan (NSDQ:MYL), have pointed to middlemen such as pharmacy-benefit managers as contributing to a complex healthcare system where transparent drug pricing is a challenge. They claim that list prices don’t take into account discounts and rebates provided to pharmacy-benefit managers and that expanding their patient-assistance programs will help patients cover their out-of-pocket costs.

But patients with high-deductible health plans sometimes have to pay close to full price for their treatments and drug-makers face increasing pressure to explain away price hikes as dramatic as 5,500%.

After winning FDA approval for its muscular dystrophy drug earlier this month, Marathon Pharmaceuticals set the drug’s list price at $89,000 a year – 50 to 70 times greater than what most U.S. patients have paid for decades by importing the drug from Europe.

Chief financial officer Babar Ghias asserted that the company showed restraint when pricing the drug. “It’s modestly priced for an orphan drug,” he said, according to The Wall Street Journal. 

Some companies, including Johnson & Johnson (NYSE:JNJ) and Merck (NYSE:MRK), have said they will issue reports detailing how much the companies have hiked the list prices of their prescription drugs.

The move comes after some pharmaceutical companies, including Allergan (NYSE:AGN) and Novo Nordisk (NYSE:NVO), have pledged to keep their annual price increases to single-digit percentages. When Allergan published its “social contract” in September, CEO Brent Saunders challenged other companies to limit price increases “before we all face the impact of government regulation that stifles innovation and patient care.”

According to Raymond James & Associates’ report, Allergan raised list prices for its drugs on average by 7.4% in January, but Saunders said his company will ultimately collect only 2 or 3% and share the rest with middlemen.

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Allergan, johnsonandjohnson, Marathon Pharmaceuticals, Merck, Mylan, Novo Nordisk

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS